Eli Lilly and Novo Nordisk currently dominate the market for the new class of GLP-1 receptor agonist medications, which work by mimicking the effect of a gut hormone that reduces appetite.

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.

Eli Lilly announced that it is expanding its offerings of its hit weight loss drug Zepbound on Tuesday, a few days after the Food and Drug Administration lifted a shortage on Novo Nordisk’s Wegovy and ...

Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...